Nuclear Medicine/Radiopharmaceuticals Global Market – Forecast To 2030
Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, studying disease progression and assessing treatment responses.
The nuclear medicine global market is poised to grow at a mid single digit CAGR from 2021 to 2030 to reach $11,362.0 million by 2030. Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy-based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.
The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market and is expected to grow at a mid single digit CAGR from 2021 to 2030 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at double digit CAGR from 2021 to 2030 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnostics market based on products is segmented into SPECT and PET among which, SPECT market commanded the largest revenue in 2021 and is expected grow at low single digit CAGR from 2021 to 2030 due to an increase in TC-99m isotope applications and product approvals. The SPECT market is further segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xenon (Xe-133), Rhenium (Re-186) and others. Among them, Technetium (Tc-99m) accounted for the largest share in 2021 and is projected to grow at low single digit CAGR from 2021 to 2030 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market based on application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. The cardiology segment accounted for the largest share in 2021 and is expected to grow at low single digit CAGR from 2021 to 2030 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2021 to 2030 due to the increasing use of SPECT isotopes in early screening tests in vulnerable populations in various developed countries.
PET is projected to grow at mid single digit CAGR from 2021 to 2030 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2021 and the market is expected to grow at mid single digit CAGR from 2021 to 2030. Gallium (Ga-68) is expected to grow at high teen CAGR from 2021 to 2030 due to an increase in usage as theranostic pair in assessing the suitability of the patient for Lutathera and many emerging targeted radiotherapy agents. PET isotopes based on applications are further segmented into oncology, neurology, cardiology, inflammation and others. The oncology segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia-related conditions.
The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. The beta radiation segment accounted for the largest share in 2021 and is projected to grow at mid double digit CAGR from 2021 to 2030. Beta radiation therapy based on isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. The Lu-177 segment commanded the largest share in 2021 and is expected to grow at double digit CAGR from 2021 to 2030 due to the increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumors and the anticipated launch of new treatment products based on the isotope. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others, among which, I-125 segment accounted for the largest share in 2021 and is projected to grow at mid single digit CAGR from 2021 to 2030 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. The therapeutic nuclear medicine market based on application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others, among which, The GEP-NETs market accounted for the largest share in 2021 and is expected to grow at mid teen CAGR from 2021 to 2030. Prostate Cancer is expected to grow at mid teen CAGR from 2021 to 2030 due to the advanced clinical trial stage (phase 3) and the predicted launch of the Lu-177 PSMA-617 product in the coming years.
The nuclear medicine market based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers, and others, among which, the hospitals segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.
Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).
The nuclear medicine global market is poised to grow at a mid single digit CAGR from 2021 to 2030 to reach $11,362.0 million by 2030. Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy-based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.
The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market and is expected to grow at a mid single digit CAGR from 2021 to 2030 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at double digit CAGR from 2021 to 2030 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnostics market based on products is segmented into SPECT and PET among which, SPECT market commanded the largest revenue in 2021 and is expected grow at low single digit CAGR from 2021 to 2030 due to an increase in TC-99m isotope applications and product approvals. The SPECT market is further segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xenon (Xe-133), Rhenium (Re-186) and others. Among them, Technetium (Tc-99m) accounted for the largest share in 2021 and is projected to grow at low single digit CAGR from 2021 to 2030 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market based on application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. The cardiology segment accounted for the largest share in 2021 and is expected to grow at low single digit CAGR from 2021 to 2030 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2021 to 2030 due to the increasing use of SPECT isotopes in early screening tests in vulnerable populations in various developed countries.
PET is projected to grow at mid single digit CAGR from 2021 to 2030 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2021 and the market is expected to grow at mid single digit CAGR from 2021 to 2030. Gallium (Ga-68) is expected to grow at high teen CAGR from 2021 to 2030 due to an increase in usage as theranostic pair in assessing the suitability of the patient for Lutathera and many emerging targeted radiotherapy agents. PET isotopes based on applications are further segmented into oncology, neurology, cardiology, inflammation and others. The oncology segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia-related conditions.
The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. The beta radiation segment accounted for the largest share in 2021 and is projected to grow at mid double digit CAGR from 2021 to 2030. Beta radiation therapy based on isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. The Lu-177 segment commanded the largest share in 2021 and is expected to grow at double digit CAGR from 2021 to 2030 due to the increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumors and the anticipated launch of new treatment products based on the isotope. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others, among which, I-125 segment accounted for the largest share in 2021 and is projected to grow at mid single digit CAGR from 2021 to 2030 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. The therapeutic nuclear medicine market based on application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others, among which, The GEP-NETs market accounted for the largest share in 2021 and is expected to grow at mid teen CAGR from 2021 to 2030. Prostate Cancer is expected to grow at mid teen CAGR from 2021 to 2030 due to the advanced clinical trial stage (phase 3) and the predicted launch of the Lu-177 PSMA-617 product in the coming years.
The nuclear medicine market based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers, and others, among which, the hospitals segment accounted for the largest share in 2021 and is projected to grow at high single digit CAGR from 2021 to 2030 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.
Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAY
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
2.6.7.1 Procedural volume assumptions
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing applications of radiopharmaceuticals
3.3.1.2 Production of radiopharmaceuticals from cyclotrons
3.3.1.3 Efficient diagnosis and treatments
3.3.1.4 Increasing interest in theranostics
3.3.1.5 Rise in public awareness
3.3.1.6 Technological advancements
3.3.1.7 Increasing demand in emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 The shorter half-life of radiopharmaceuticals
3.3.2.2 High cost and supply shortage of isotopes
3.3.2.3 Radio toxicity
3.3.2.4 Shortage of qualified technicians
3.3.2.5 Withdrawal of radiopharmacy products due to limited commercial adoption
3.3.2.6 Regulatory issues
3.3.2.7 Threat from traditional/alternative diagnostic procedures
3.3.2.8 Huge capital investment
3.4 PROBLEM AREAS
3.4.1 CLOSURE OF REACTORS
3.5 WINNING IMPERATIVES
3.5.1 AVAILABILITY OF TECHNETIUM
3.6 REGULATORY GUIDELINES
3.6.1 UNITED STATES
3.6.2 EUROPE
3.6.3 JAPAN
3.6.4 INDIA
3.6.5 CHINA
3.6.6 SOUTH KOREA
3.6.7 SOUTH AFRICA
3.7 REIMBURSEMENT SCENARIO AND CHALLENGES
3.8 CLINICAL TRIALS
3.9 TECHNOLOGICAL ADVANCEMENTS
3.9.1 COMPTON CAMERA
3.9.2 SUBTLE PET
3.9.3 PRODUCTION OF ISOTOPES THROUGH CYCLOTRONS
3.9.4 LINAC BASED TC-99M PRODUCTION
3.9.5 AUGER ELECTRONS
3.10 SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
3.10.1 REACTORS/IRRADIATORS
3.10.2 PROCESSING FACILITY
3.10.3 GENERATORS
3.10.4 HOSPITALS AND CENTRAL RADIO PHARMACIES
3.10.5 CYCLOTRON
3.10.6 LINAC BASED TC-99M PRODUCTION METHOD
3.11 LIST OF FDA APPROVED RADIOPHARMACEUTICALS
3.12 PORTER'S FIVE FORCE ANALYSIS
3.12.1 THREAT OF NEW ENTRANTS
3.12.2 THREAT OF SUBSTITUTES
3.12.3 COMPETITIVE RIVALRY
3.12.4 BARGAINING POWER OF SUPPLIERS
3.12.5 BARGAINING POWER OF BUYERS
3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.13.1 NUCLEAR MEDICINE MARKET
3.13.2 SPECT MARKET
3.13.3 PET MARKET
3.13.4 NUCLEAR MEDICINE THERAPEUTICS MARKET
3.13.5 TC-99 MARKET
3.13.6 F-18 MARKET
3.13.7 GA-68 MARKET
3.13.8 SR-82/RB-82 MARKET (IRRADIATORS, SEPERATION AND GENERATORS)
3.14 NUCLEAR MEDICINE-FUNDING SCENARIO
3.15 NUCLEAR MEDICINE – DEALS AND APPROVALS
3.16 SPECT, PET AND CYCLOTRONS INSTALLED BASE
3.17 CURRENT PRODUCTION CAPACITY AND DEMAND OF SELECT ISOTOPES
3.18 EMERGING ISOTOPES
3.19 LIST OF ISOTOPES PRODUCED USING 70 MEV CYCLOTRON AND COST ANALYSIS
4 NUCLEAR MEDICINE GLOBAL MARKET, BASED ON MODALITY
4.1 INTRODUCTION
4.2 DIAGNOSTICS
4.2.1 DIAGNOSTIC NUCLEAR MEDICINE BASED ON ISOTOPES
4.2.1.1 SPECT, based on isotopes
4.2.1.1.1 Technetium (Tc-99m)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.4.1 Supply Chain Analysis Of Iodine-123 (I-123)
4.2.1.1.5 Xenon (Xe-133)
4.2.1.1.6 Rhenium (Re-186)
4.2.1.1.7 Others (In-111, Y-90, Cr-51)
4.2.1.2 PET, based on isotopes
4.2.1.2.1 Fluorodeoxyglucose (18f-FDG)
4.2.1.2.1.1 Supply Chain Analysis Of Fluorine-18 (F-18)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.2.1 Supply Chain Analysis Of Gallium-68 (Ga-68)
4.2.1.2.2.2 Characteristics Of Current Ge-68/Ga-68 Generators
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.3.1 Production analysis of Strontium (Sr-82)/ Rubidium (Rb-82)
4.2.1.2.4 Others (C-11, N-13, O-15, Cu-64)
4.2.2 NUCLEAR MEDICINE FOR DIAGNOSIS, BASED ON APPLICATION
4.2.2.1 SPECT isotopes based on application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 PET isotopes, based on application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 THERAPEUTICS
4.3.1 BETA RADIATION THERAPY
4.3.1.1 Yttrium (Y-90)
4.3.1.2 Iodine (I-131)
4.3.1.3 Lutetium (Lu-177)
4.3.1.3.1 Demand and production analysis of Lutetium-177 (Lu-177)
4.3.1.4 Samarium (Sm-153)
4.3.1.5 Rhenium (Re-186)
4.3.1.6 Strontium (Sr-89)
4.3.1.7 Erbium (Er-169)
4.3.1.8 Others
4.3.2 ALPHA RADIATION THERAPY
4.3.2.1 Radium (Ra-223)
4.3.2.1.1 Analysis of Radium-223 (Ra-223)
4.3.2.2 Emerging alpha radiation isotopes (Ac-225 and Others)
4.3.2.2.1 Production analysis of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213)
4.3.2.2.2 Astatine (At-211)
4.3.2.2.3 Lead (Pb-212)/Bismuth (Bi-212)
4.3.2.2.4 Radium (Ra-224)
4.3.2.2.5 Thorium(Th-227)
4.3.2.2.6 Others
4.3.3 BRACHYTHERAPY, BASED ON ISOTOPES
4.3.3.1 Iodine (I-125)
4.3.3.2 Cesium (Cs-131)
4.3.3.3 Iridium (Ir-192)
4.3.3.4 Palladium (Pd-103)
4.3.3.5 Others
4.3.4 NUCLEAR MEDICINE THERAPEUTICS, BASED ON APPLICATION
4.3.4.1 Prostate Cancer
4.3.4.2 Thyroid Cancer
4.3.4.3 Liver Cancer
4.3.4.4 Gep-Net Therapeutics
4.3.4.5 Metastatic Bone Cancer Therapeutics
4.3.4.6 Breast Cancer Therapeutics
4.3.4.7 Other applications
5 NUCLEAR MEDICINE GLOBAL MARKET, BASED ON END-USERS
5.1 INTRODUCTION
5.2 HOSPITALS
5.3 AMBULATORY CENTERS
5.4 DIAGNOSTIC CENTERS
5.5 OTHER END-USERS
6 NUCLEAR MEDICINE GLOBAL MARKET BASED ON REGION
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.2.1 U.S.
6.2.2 REST OF N.A.
6.3 EUROPE
6.3.1 GERMANY
6.3.2 FRANCE
6.3.3 ITALY
6.3.4 REST OF E.U.
6.4 APAC
6.4.1 JAPAN
6.4.2 CHINA
6.4.3 SOUTH KOREA
6.4.4 REST OF APAC
6.5 REST OF THE WORLD
6.5.1 LATIN AMERICA & CARIBBEAN
6.5.2 MIDDLE EAST
6.5.3 AFRICA
6.5.3.1 SOUTH AFRICA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 APPROVALS
7.3 AGREEMENT/COLLABORATION
7.4 ACQUISITION
7.5 PRODUCT LAUNCH
7.6 OTHERS
8 MAJOR PLAYER PROFILES
8.1 BAYER GROUP
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 BRACCO S.P.A
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 CARDINAL HEALTH INC.
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 CURIUM PHARMA
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 FUJIFILM HOLDINGS CORPORATION
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 GE HEALTHCARE
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 JUBILANT PHARMOVA
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 LANTHEUS MEDICAL IMAGING INC.
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 NOVARTIS INTERNATIONAL AG
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
8.11 SUMITOMO CHEMICALS
8.11.1 OVERVIEW
8.11.2 FINANCIALS
8.11.3 PRODUCT PORTFOLIO
8.11.4 KEY DEVELOPMENTS
8.11.5 BUSINESS STRATEGY
8.11.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKE AWAY
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
2.6.7.1 Procedural volume assumptions
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing applications of radiopharmaceuticals
3.3.1.2 Production of radiopharmaceuticals from cyclotrons
3.3.1.3 Efficient diagnosis and treatments
3.3.1.4 Increasing interest in theranostics
3.3.1.5 Rise in public awareness
3.3.1.6 Technological advancements
3.3.1.7 Increasing demand in emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 The shorter half-life of radiopharmaceuticals
3.3.2.2 High cost and supply shortage of isotopes
3.3.2.3 Radio toxicity
3.3.2.4 Shortage of qualified technicians
3.3.2.5 Withdrawal of radiopharmacy products due to limited commercial adoption
3.3.2.6 Regulatory issues
3.3.2.7 Threat from traditional/alternative diagnostic procedures
3.3.2.8 Huge capital investment
3.4 PROBLEM AREAS
3.4.1 CLOSURE OF REACTORS
3.5 WINNING IMPERATIVES
3.5.1 AVAILABILITY OF TECHNETIUM
3.6 REGULATORY GUIDELINES
3.6.1 UNITED STATES
3.6.2 EUROPE
3.6.3 JAPAN
3.6.4 INDIA
3.6.5 CHINA
3.6.6 SOUTH KOREA
3.6.7 SOUTH AFRICA
3.7 REIMBURSEMENT SCENARIO AND CHALLENGES
3.8 CLINICAL TRIALS
3.9 TECHNOLOGICAL ADVANCEMENTS
3.9.1 COMPTON CAMERA
3.9.2 SUBTLE PET
3.9.3 PRODUCTION OF ISOTOPES THROUGH CYCLOTRONS
3.9.4 LINAC BASED TC-99M PRODUCTION
3.9.5 AUGER ELECTRONS
3.10 SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
3.10.1 REACTORS/IRRADIATORS
3.10.2 PROCESSING FACILITY
3.10.3 GENERATORS
3.10.4 HOSPITALS AND CENTRAL RADIO PHARMACIES
3.10.5 CYCLOTRON
3.10.6 LINAC BASED TC-99M PRODUCTION METHOD
3.11 LIST OF FDA APPROVED RADIOPHARMACEUTICALS
3.12 PORTER'S FIVE FORCE ANALYSIS
3.12.1 THREAT OF NEW ENTRANTS
3.12.2 THREAT OF SUBSTITUTES
3.12.3 COMPETITIVE RIVALRY
3.12.4 BARGAINING POWER OF SUPPLIERS
3.12.5 BARGAINING POWER OF BUYERS
3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.13.1 NUCLEAR MEDICINE MARKET
3.13.2 SPECT MARKET
3.13.3 PET MARKET
3.13.4 NUCLEAR MEDICINE THERAPEUTICS MARKET
3.13.5 TC-99 MARKET
3.13.6 F-18 MARKET
3.13.7 GA-68 MARKET
3.13.8 SR-82/RB-82 MARKET (IRRADIATORS, SEPERATION AND GENERATORS)
3.14 NUCLEAR MEDICINE-FUNDING SCENARIO
3.15 NUCLEAR MEDICINE – DEALS AND APPROVALS
3.16 SPECT, PET AND CYCLOTRONS INSTALLED BASE
3.17 CURRENT PRODUCTION CAPACITY AND DEMAND OF SELECT ISOTOPES
3.18 EMERGING ISOTOPES
3.19 LIST OF ISOTOPES PRODUCED USING 70 MEV CYCLOTRON AND COST ANALYSIS
4 NUCLEAR MEDICINE GLOBAL MARKET, BASED ON MODALITY
4.1 INTRODUCTION
4.2 DIAGNOSTICS
4.2.1 DIAGNOSTIC NUCLEAR MEDICINE BASED ON ISOTOPES
4.2.1.1 SPECT, based on isotopes
4.2.1.1.1 Technetium (Tc-99m)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.4.1 Supply Chain Analysis Of Iodine-123 (I-123)
4.2.1.1.5 Xenon (Xe-133)
4.2.1.1.6 Rhenium (Re-186)
4.2.1.1.7 Others (In-111, Y-90, Cr-51)
4.2.1.2 PET, based on isotopes
4.2.1.2.1 Fluorodeoxyglucose (18f-FDG)
4.2.1.2.1.1 Supply Chain Analysis Of Fluorine-18 (F-18)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.2.1 Supply Chain Analysis Of Gallium-68 (Ga-68)
4.2.1.2.2.2 Characteristics Of Current Ge-68/Ga-68 Generators
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.3.1 Production analysis of Strontium (Sr-82)/ Rubidium (Rb-82)
4.2.1.2.4 Others (C-11, N-13, O-15, Cu-64)
4.2.2 NUCLEAR MEDICINE FOR DIAGNOSIS, BASED ON APPLICATION
4.2.2.1 SPECT isotopes based on application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 PET isotopes, based on application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 THERAPEUTICS
4.3.1 BETA RADIATION THERAPY
4.3.1.1 Yttrium (Y-90)
4.3.1.2 Iodine (I-131)
4.3.1.3 Lutetium (Lu-177)
4.3.1.3.1 Demand and production analysis of Lutetium-177 (Lu-177)
4.3.1.4 Samarium (Sm-153)
4.3.1.5 Rhenium (Re-186)
4.3.1.6 Strontium (Sr-89)
4.3.1.7 Erbium (Er-169)
4.3.1.8 Others
4.3.2 ALPHA RADIATION THERAPY
4.3.2.1 Radium (Ra-223)
4.3.2.1.1 Analysis of Radium-223 (Ra-223)
4.3.2.2 Emerging alpha radiation isotopes (Ac-225 and Others)
4.3.2.2.1 Production analysis of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213)
4.3.2.2.2 Astatine (At-211)
4.3.2.2.3 Lead (Pb-212)/Bismuth (Bi-212)
4.3.2.2.4 Radium (Ra-224)
4.3.2.2.5 Thorium(Th-227)
4.3.2.2.6 Others
4.3.3 BRACHYTHERAPY, BASED ON ISOTOPES
4.3.3.1 Iodine (I-125)
4.3.3.2 Cesium (Cs-131)
4.3.3.3 Iridium (Ir-192)
4.3.3.4 Palladium (Pd-103)
4.3.3.5 Others
4.3.4 NUCLEAR MEDICINE THERAPEUTICS, BASED ON APPLICATION
4.3.4.1 Prostate Cancer
4.3.4.2 Thyroid Cancer
4.3.4.3 Liver Cancer
4.3.4.4 Gep-Net Therapeutics
4.3.4.5 Metastatic Bone Cancer Therapeutics
4.3.4.6 Breast Cancer Therapeutics
4.3.4.7 Other applications
5 NUCLEAR MEDICINE GLOBAL MARKET, BASED ON END-USERS
5.1 INTRODUCTION
5.2 HOSPITALS
5.3 AMBULATORY CENTERS
5.4 DIAGNOSTIC CENTERS
5.5 OTHER END-USERS
6 NUCLEAR MEDICINE GLOBAL MARKET BASED ON REGION
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.2.1 U.S.
6.2.2 REST OF N.A.
6.3 EUROPE
6.3.1 GERMANY
6.3.2 FRANCE
6.3.3 ITALY
6.3.4 REST OF E.U.
6.4 APAC
6.4.1 JAPAN
6.4.2 CHINA
6.4.3 SOUTH KOREA
6.4.4 REST OF APAC
6.5 REST OF THE WORLD
6.5.1 LATIN AMERICA & CARIBBEAN
6.5.2 MIDDLE EAST
6.5.3 AFRICA
6.5.3.1 SOUTH AFRICA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 APPROVALS
7.3 AGREEMENT/COLLABORATION
7.4 ACQUISITION
7.5 PRODUCT LAUNCH
7.6 OTHERS
8 MAJOR PLAYER PROFILES
8.1 BAYER GROUP
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 BRACCO S.P.A
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 CARDINAL HEALTH INC.
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 CURIUM PHARMA
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 FUJIFILM HOLDINGS CORPORATION
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 GE HEALTHCARE
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 JUBILANT PHARMOVA
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 LANTHEUS MEDICAL IMAGING INC.
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 NOVARTIS INTERNATIONAL AG
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
8.11 SUMITOMO CHEMICALS
8.11.1 OVERVIEW
8.11.2 FINANCIALS
8.11.3 PRODUCT PORTFOLIO
8.11.4 KEY DEVELOPMENTS
8.11.5 BUSINESS STRATEGY
8.11.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 2 REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
TABLE 3 NUCLEAR MEDICINE CLINICAL TRIALS
TABLE 4 TECHNETIUM (TC-99M) CURRENT IRRADIATORS
TABLE 5 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 6 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 7 TECHNETIUM (TC-99M) CURRENT PROCESSORS
TABLE 8 POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
TABLE 9 FDA APPROVED RADIOPHARMACEUTICALS
TABLE 10 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 11 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2020-2030) ($MN)
TABLE 12 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 13 NUCLEAR MEDICINE SPECT AND PET OVERALL PROCEDURAL VOLUME (2021) (NOS.)
TABLE 14 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 15 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 16 TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 17 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 18 GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 19 IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 20 XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 21 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 22 OTHER SPECT ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 23 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 24 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 25 FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 26 GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 27 GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
TABLE 28 RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 29 STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
TABLE 30 OTHER PET ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 31 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 32 CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 33 PULMONARY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 34 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 35 NEPHROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 36 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 37 INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 38 THYROID GLANDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 39 LYMPHOLOGY SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 40 OTHER SPECT APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 41 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 42 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 43 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 44 CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 45 INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 46 OTHER PET APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 47 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 48 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 49 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 50 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 51 YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 52 IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 53 LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY
TABLE 54 LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 55 LUTETIUM (LU-177) NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2021
TABLE 56 SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 57 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 58 STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 59 ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 60 OTHER BETA RADIATION THERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 61 ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 62 ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS
TABLE 63 ASTATINE (AT-211) CURRENT SUPPLIERS
TABLE 64 BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 65 BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 66 IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 67 CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 68 IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 69 PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 70 OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 71 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 72 PROSTATE CANCER THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 73 THYROID CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 74 LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 75 GEP-NET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 76 METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 77 BREAST CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 78 OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 79 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 80 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 81 AMBULATORY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 82 DIAGNOSTIC CENTERS END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 83 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 84 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 85 NORTH AMERICA INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 86 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 87 NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 88 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 89 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 90 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 91 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 92 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 93 NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 94 NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 95 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 96 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 97 NORTH AMERICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 98 EUROPE INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 99 EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 100 EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 101 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 102 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 103 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 104 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 105 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 106 EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 107 EUROPE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 108 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 109 EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 110 EUROPE NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 111 APAC INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 112 APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 113 APAC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 114 APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 115 APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 116 APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 117 APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 118 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 119 APAC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 120 APAC BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 121 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 122 APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 123 APAC NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 124 ROW INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 125 ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 126 ROW NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 127 ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 128 ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 129 ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 130 ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 131 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 132 ROW NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 133 ROW BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 134 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 135 ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 136 ROW NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 137 AFRICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($ K)
TABLE 138 SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($ K)
TABLE 139 SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($ K)
TABLE 140 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 141 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 142 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 143 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 144 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($ K)
TABLE 145 SOUTH AFRICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 146 SOUTH AFRICA BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 147 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 148 SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($ K)
TABLE 149 APPROVALS (2019-2020)
TABLE 150 COLLABORATION (2020-2021)
TABLE 151 ACQUISITION (2020-2021)
TABLE 152 PRODUCT LAUNCH (2020-2021)
TABLE 153 OTHERS (2020-2021)
TABLE 154 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 155 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 156 BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 157 CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2019-2021) ($MN)
TABLE 158 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2019 -2021) ($MN)
TABLE 159 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
TABLE 160 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
TABLE 161 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 162 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
TABLE 163 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q3) ($MN)
TABLE 164 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 165 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q2) ($MN)
TABLE 166 JUBILANT PHARMOVA: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q2) ($MN)
TABLE 167 JUBILANT PHARMOVA: TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
TABLE 168 JUBILANT PHARMOVA: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
TABLE 169 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 170 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
TABLE 171 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)
TABLE 172 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 173 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 174 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 175 SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
TABLE 176 SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 177 SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
TABLE 1 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 2 REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
TABLE 3 NUCLEAR MEDICINE CLINICAL TRIALS
TABLE 4 TECHNETIUM (TC-99M) CURRENT IRRADIATORS
TABLE 5 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 6 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 7 TECHNETIUM (TC-99M) CURRENT PROCESSORS
TABLE 8 POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
TABLE 9 FDA APPROVED RADIOPHARMACEUTICALS
TABLE 10 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 11 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2020-2030) ($MN)
TABLE 12 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 13 NUCLEAR MEDICINE SPECT AND PET OVERALL PROCEDURAL VOLUME (2021) (NOS.)
TABLE 14 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 15 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 16 TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 17 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 18 GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 19 IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 20 XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 21 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 22 OTHER SPECT ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 23 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 24 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 25 FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 26 GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 27 GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
TABLE 28 RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 29 STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
TABLE 30 OTHER PET ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 31 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 32 CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 33 PULMONARY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 34 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 35 NEPHROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 36 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 37 INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 38 THYROID GLANDS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 39 LYMPHOLOGY SPECT GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 40 OTHER SPECT APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 41 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 42 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 43 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 44 CARDIOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 45 INFLAMMATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 46 OTHER PET APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 47 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 48 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 49 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 50 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 51 YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 52 IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 53 LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY
TABLE 54 LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 55 LUTETIUM (LU-177) NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2021
TABLE 56 SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 57 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 58 STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 59 ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 60 OTHER BETA RADIATION THERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 61 ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 62 ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS
TABLE 63 ASTATINE (AT-211) CURRENT SUPPLIERS
TABLE 64 BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 65 BRACHYTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 66 IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 67 CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 68 IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 69 PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 70 OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 71 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 72 PROSTATE CANCER THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 73 THYROID CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 74 LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 75 GEP-NET GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 76 METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 77 BREAST CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 78 OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 79 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 80 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 81 AMBULATORY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 82 DIAGNOSTIC CENTERS END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 83 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 84 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2030) ($MN)
TABLE 85 NORTH AMERICA INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 86 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 87 NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 88 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 89 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 90 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 91 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 92 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 93 NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 94 NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 95 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 96 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 97 NORTH AMERICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 98 EUROPE INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 99 EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 100 EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 101 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 102 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 103 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 104 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 105 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 106 EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 107 EUROPE BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 108 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 109 EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 110 EUROPE NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 111 APAC INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 112 APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 113 APAC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 114 APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPE, (2020-2030) ($MN)
TABLE 115 APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 116 APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 117 APAC NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 118 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 119 APAC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 120 APAC BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 121 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATIONS, (2020-2030) ($MN)
TABLE 122 APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 123 APAC NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 124 ROW INSTALLED BASE OF SPECT, PET DEVICES AND CYCLOTRONS
TABLE 125 ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($MN)
TABLE 126 ROW NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($MN)
TABLE 127 ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 128 ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 129 ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 130 ROW NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 131 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($MN)
TABLE 132 ROW NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 133 ROW BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($MN)
TABLE 134 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($MN)
TABLE 135 ROW NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($MN)
TABLE 136 ROW NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($MN)
TABLE 137 AFRICA NUCLEAR MEDICINES MARKET REVENUE, BASED ON COUNTRY, (2020-2030) ($ K)
TABLE 138 SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, (2020-2030) ($ K)
TABLE 139 SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BASED ON PRODUCTS, (2020-2030) ($ K)
TABLE 140 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 141 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 142 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 143 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 144 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON RADIATION TYPE, (2020-2030) ($ K)
TABLE 145 SOUTH AFRICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 146 SOUTH AFRICA BRACHYTHERAPY MARKET REVENUE, BASED ON ISOTOPES, (2020-2030) ($ K)
TABLE 147 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION, (2020-2030) ($ K)
TABLE 148 SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2020-2030) ($ K)
TABLE 149 APPROVALS (2019-2020)
TABLE 150 COLLABORATION (2020-2021)
TABLE 151 ACQUISITION (2020-2021)
TABLE 152 PRODUCT LAUNCH (2020-2021)
TABLE 153 OTHERS (2020-2021)
TABLE 154 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 155 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 156 BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 157 CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2019-2021) ($MN)
TABLE 158 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2019 -2021) ($MN)
TABLE 159 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
TABLE 160 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
TABLE 161 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 162 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
TABLE 163 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q3) ($MN)
TABLE 164 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 165 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q2) ($MN)
TABLE 166 JUBILANT PHARMOVA: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q2) ($MN)
TABLE 167 JUBILANT PHARMOVA: TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
TABLE 168 JUBILANT PHARMOVA: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2019–2021) (Q2) ($MN)
TABLE 169 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 170 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
TABLE 171 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)
TABLE 172 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 173 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 174 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 175 SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
TABLE 176 SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 177 SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
LIST OF FIGURES
FIGURE 1 NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BASED ON REGION, (2020-2030) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
FIGURE 3 NUCLEAR MEDICINE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 DIAGNOSTICS NUCLEAR GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 8 THERAPEUTIC NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 9 MARKET DYNAMICS
FIGURE 10 TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
FIGURE 11 NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS
FIGURE 12 NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2021 (%)
FIGURE 13 SPECT ISOTOPES: MAJOR PLAYER MARKET SHARE ANALYSIS (2021) (%)
FIGURE 14 PET ISOTOPES: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 15 NUCLEAR MEDICINE THERAPEUTICS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 16 Tc -99m: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 17 F-18: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 18 Ga-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 19 Sr-82 IRRADIATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 20 SR-82 SEPARATION: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 21 SR-82/RB-82 GENERATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 22 SPECT SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 23 PET SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 24 CYCLOTRONS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 25 NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON MODALITY, (2021 V/S 2030) (%)
FIGURE 26 NUCLEAR MEDICINE ISOTOPES, BASED ON MODALITY
FIGURE 27 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET SHARE, BASED ON PRODUCTS, (2021 V/S 2030) (%)
FIGURE 28 SPECT GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021) (NOS.)
FIGURE 29 PET GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021)(NOS.)
FIGURE 30 NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 31 THALLIUM (TL-201) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 32 GALLIUM (GA-67) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 33 IODINE (I-123) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 34 IODINE (I-123) SUPPLY CHAIN
FIGURE 35 XENON (XE-133) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 36 RHENIUM (RE-186) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 37 NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 38 FLUORINE-18 (F-18) SUPPLY CHAIN
FIGURE 39 SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
FIGURE 40 NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 41 NUCLEAR MEDICINE SPECT ISOTOPES, BASED ON APPLICATION
FIGURE 42 CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 43 NEPHROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 44 NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 45 INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 46 NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 47 NUCLEAR MEDICINE PET ISOTOPES, BASED ON APPLICATION
FIGURE 48 CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 49 INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 50 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 51 BETA RADIATION THERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 52 IODINE(I-131) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 53 LU-177 BASED THERAPY (LUTATHERA), GLOBAL MARKET PENETRATION, (2021) (%)
FIGURE 54 LU-177 BASED THERAPY (LUTATHERA), NORTH AMERICA MARKET PENETRATION, (2021) (%)
FIGURE 55 LU-177 BASED THERAPY (LUTATHERA), EUROPE MARKET PENETRATION, (2021)(%)
FIGURE 56 LU-177 BASED THERAPY (LUTATHERA), ASIA-PACIFIC MARKET PENETRATION, (2021) (%)
FIGURE 57 LU-177 BASED THERAPY (LUTATHERA), ROW MARKET PENETRATION, (2021) (%)
FIGURE 58 SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 59 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 60 ERBIUM (ER-169) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 61 NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 62 BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 63 IODINE (I-125) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 64 CESIUM (CS-131) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 65 IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 66 PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 67 OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 68 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 69 NUCLEAR MEDICINE THERAPEUTIC ISOTOPES, BASED ON APPLICATION
FIGURE 70 PROSTATE CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 71 THYROID CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 72 BREAST CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 73 NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON END-USERS, (2021 V/S 2030) (%)
FIGURE 74 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION (2020-2030) ($MN), CAGR (%)
FIGURE 75 NUCLEAR MEDICINE GLOBAL MARKET SHARE BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY, (2021) (%) ($MN)
FIGURE 76 NORTH AMERICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 77 NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BASED ON PRODUCT, (2021 V/S 2030) (%)
FIGURE 78 NORTH AMERICA SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 79 NORTH AMERICA PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 80 NORTH AMERICA SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 81 NORTH AMERICA PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 82 NORTH AMERICA THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 83 NORTH AMERICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 84 NORTH AMERICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 85 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 86 NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 87 NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
FIGURE 88 U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 89 U.S. NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 90 U.S. NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 91 REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 92 REST OF NORTH AMERICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 93 REST OF NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 94 EUROPE NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 95 EUROPE NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 96 EUROPE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 97 EUROPE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 98 EUROPE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 99 EUROPE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 100 EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 101 EUROPE BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 102 EUROPE BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 103 EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 104 EUROPE NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 105 EUROPE NUCLEAR MEDICINE SHARE, BY COUNTRY, (2021 V/S 2030) (%)
FIGURE 106 GERMANY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND GERMANY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 107 GERMANY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 108 GERMANY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 109 FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND FRANCE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 110 FRANCE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 111 FRANCE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 112 ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND ITALY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 113 ITALY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 114 ITALY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 115 REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND REST OF EUROPE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 116 REST OF EUROPE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 117 REST OF EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 118 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 119 APAC NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 120 APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 121 APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 122 APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 123 APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 124 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET SHARE, BY RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 125 APAC BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 126 APAC BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 127 APAC NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 128 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 129 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
FIGURE 130 JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND JAPAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 131 JAPAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 132 JAPAN NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 133 CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND CHINA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 134 CHINA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 135 CHINA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 136 SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND SOUTH KOREA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 137 SOUTH KOREA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 138 SOUTH KOREA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 139 REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, AND THE REST OF APAC DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 140 REST OF APAC NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 141 REST OF APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 142 ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 143 ROW NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 144 ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 145 ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 146 ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 147 ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 148 ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 149 ROW BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 150 ROW BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 151 ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 152 ROW NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
FIGURE 153 ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
FIGURE 154 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND LATIN AMERICA & CARIBBEAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030)($MN)
FIGURE 155 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 156 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 157 MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND MIDDLE EAST DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 158 MIDDLE EAST NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 159 MIDDLE EAST NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 160 AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND AFRICA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 161 AFRICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 162 AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 163 AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
FIGURE 164 SOUTH AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 165 SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 166 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 167 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 168 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 169 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 170 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 171 SOUTH AFRICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 172 SOUTH AFRICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 173 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 174 SOUTH AFRICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
FIGURE 175 KEY GROWTH STRATEGIES (2020-2021)
FIGURE 176 SWOT: BAYER GROUP
FIGURE 177 SWOT: BRACCO S.P.A
FIGURE 178 SWOT: CARDINAL HEALTH, INC.
FIGURE 179 SWOT: CDH INVESTMENTS
FIGURE 180 SWOT: CURIUM PHARMA
FIGURE 181 SWOT: FUJIFILM HOLDING CORPORATION
FIGURE 182 SWOT: GE HEALTHCARE
FIGURE 183 SWOT: JUBILANT LIFESCIENCES
FIGURE 184 SWOT: LANTHEUS MEDICAL IMAGING INC.
FIGURE 185 SWOT: NOVARTIS INTERNATIONAL AG
FIGURE 186 SWOT: SUMITOMO CHEMICALS
FIGURE 1 NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BASED ON REGION, (2020-2030) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
FIGURE 3 NUCLEAR MEDICINE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 DIAGNOSTICS NUCLEAR GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 8 THERAPEUTIC NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 9 MARKET DYNAMICS
FIGURE 10 TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
FIGURE 11 NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS
FIGURE 12 NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2021 (%)
FIGURE 13 SPECT ISOTOPES: MAJOR PLAYER MARKET SHARE ANALYSIS (2021) (%)
FIGURE 14 PET ISOTOPES: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 15 NUCLEAR MEDICINE THERAPEUTICS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 16 Tc -99m: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 17 F-18: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 18 Ga-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 19 Sr-82 IRRADIATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 20 SR-82 SEPARATION: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 21 SR-82/RB-82 GENERATORS: MAJOR PLAYERS MARKET SHARE ANALYSIS (2021) (%)
FIGURE 22 SPECT SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 23 PET SCANNERS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 24 CYCLOTRONS GLOBAL AND REGIONAL INSTALLED BASE (2021)
FIGURE 25 NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON MODALITY, (2021 V/S 2030) (%)
FIGURE 26 NUCLEAR MEDICINE ISOTOPES, BASED ON MODALITY
FIGURE 27 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET SHARE, BASED ON PRODUCTS, (2021 V/S 2030) (%)
FIGURE 28 SPECT GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021) (NOS.)
FIGURE 29 PET GLOBAL PROCEDURAL VOLUME BASED ON REGION AND COUNTRY (2021)(NOS.)
FIGURE 30 NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 31 THALLIUM (TL-201) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 32 GALLIUM (GA-67) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 33 IODINE (I-123) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 34 IODINE (I-123) SUPPLY CHAIN
FIGURE 35 XENON (XE-133) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 36 RHENIUM (RE-186) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 37 NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 38 FLUORINE-18 (F-18) SUPPLY CHAIN
FIGURE 39 SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
FIGURE 40 NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 41 NUCLEAR MEDICINE SPECT ISOTOPES, BASED ON APPLICATION
FIGURE 42 CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 43 NEPHROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 44 NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 45 INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 46 NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 47 NUCLEAR MEDICINE PET ISOTOPES, BASED ON APPLICATION
FIGURE 48 CARDIOLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 49 INFLAMMATION GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 50 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 51 BETA RADIATION THERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 52 IODINE(I-131) GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 53 LU-177 BASED THERAPY (LUTATHERA), GLOBAL MARKET PENETRATION, (2021) (%)
FIGURE 54 LU-177 BASED THERAPY (LUTATHERA), NORTH AMERICA MARKET PENETRATION, (2021) (%)
FIGURE 55 LU-177 BASED THERAPY (LUTATHERA), EUROPE MARKET PENETRATION, (2021)(%)
FIGURE 56 LU-177 BASED THERAPY (LUTATHERA), ASIA-PACIFIC MARKET PENETRATION, (2021) (%)
FIGURE 57 LU-177 BASED THERAPY (LUTATHERA), ROW MARKET PENETRATION, (2021) (%)
FIGURE 58 SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 59 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 60 ERBIUM (ER-169) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 61 NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 62 BRACHYTHERAPY GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 63 IODINE (I-125) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 64 CESIUM (CS-131) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 65 IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 66 PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 67 OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 68 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 69 NUCLEAR MEDICINE THERAPEUTIC ISOTOPES, BASED ON APPLICATION
FIGURE 70 PROSTATE CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 71 THYROID CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 72 BREAST CANCER GLOBAL MARKET SHARE, BASED ON REGION, (2021 V/S 2030) (%)
FIGURE 73 NUCLEAR MEDICINE GLOBAL MARKET SHARE, BASED ON END-USERS, (2021 V/S 2030) (%)
FIGURE 74 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BASED ON REGION (2020-2030) ($MN), CAGR (%)
FIGURE 75 NUCLEAR MEDICINE GLOBAL MARKET SHARE BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY, (2021) (%) ($MN)
FIGURE 76 NORTH AMERICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 77 NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BASED ON PRODUCT, (2021 V/S 2030) (%)
FIGURE 78 NORTH AMERICA SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 79 NORTH AMERICA PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 80 NORTH AMERICA SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 81 NORTH AMERICA PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 82 NORTH AMERICA THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 83 NORTH AMERICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 84 NORTH AMERICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 85 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 86 NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 87 NORTH AMERICA NUCLEAR MEDICINE SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
FIGURE 88 U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 89 U.S. NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 90 U.S. NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND U.S. NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 91 REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 92 REST OF NORTH AMERICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 93 REST OF NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 94 EUROPE NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 95 EUROPE NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 96 EUROPE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 97 EUROPE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 98 EUROPE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 99 EUROPE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 100 EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 101 EUROPE BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 102 EUROPE BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 103 EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 104 EUROPE NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 105 EUROPE NUCLEAR MEDICINE SHARE, BY COUNTRY, (2021 V/S 2030) (%)
FIGURE 106 GERMANY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND GERMANY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 107 GERMANY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 108 GERMANY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 109 FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND FRANCE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 110 FRANCE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 111 FRANCE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND FRANCE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 112 ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND ITALY DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 113 ITALY NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 114 ITALY NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND ITALY NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 115 REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND REST OF EUROPE DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 116 REST OF EUROPE NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 117 REST OF EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND REST OF EUROPE NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 118 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 119 APAC NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 120 APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 121 APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 122 APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 123 APAC NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 124 APAC NUCLEAR MEDICINE THERAPEUTICS MARKET SHARE, BY RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 125 APAC BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 126 APAC BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 127 APAC NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 128 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON END-USER, (2021 V/S 2030) (%)
FIGURE 129 APAC NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 V/S 2030) (%)
FIGURE 130 JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND JAPAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 131 JAPAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 132 JAPAN NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND JAPAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 133 CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND CHINA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 134 CHINA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 135 CHINA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND CHINA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 136 SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND SOUTH KOREA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 137 SOUTH KOREA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 138 SOUTH KOREA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BASED ON APPLICATION AND SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 139 REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY, AND THE REST OF APAC DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 140 REST OF APAC NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 141 REST OF APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND THE REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 142 ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 143 ROW NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 144 ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 145 ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 146 ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 147 ROW NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 148 ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 149 ROW BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 150 ROW BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 151 ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 152 ROW NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
FIGURE 153 ROW NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
FIGURE 154 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND LATIN AMERICA & CARIBBEAN DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030)($MN)
FIGURE 155 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 156 LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND LATIN AMERICA & CARIBBEAN NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 157 MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND MIDDLE EAST DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 158 MIDDLE EAST NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 159 MIDDLE EAST NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND MIDDLE EAST NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 160 AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON MODALITY AND AFRICA DIAGNOSTIC MARKET REVENUE, BASED ON PRODUCT (2021 V/S 2030) ($MN)
FIGURE 161 AFRICA NUCLEAR MEDICINE SPECT AND PET MARKET REVENUE, BASED ON APPLICATION, (2021 V/S 2030) ($MN)
FIGURE 162 AFRICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BASED ON APPLICATION AND AFRICA NUCLEAR MEDICINE MARKET REVENUE, BASED ON END-USERS, (2021 V/S 2030) ($MN)
FIGURE 163 AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON COUNTRY, (2021 VS 2030) (%)
FIGURE 164 SOUTH AFRICA NUCLEAR MEDICINE MARKET SHARE, BASED ON MODALITY (2021 V/S 2030) (%)
FIGURE 165 SOUTH AFRICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2021 V/S 2030) (%)
FIGURE 166 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 167 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON ISOTOPES, (2021 V/S 2030) (%)
FIGURE 168 SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET SHARE, BASED ON APPLICATION, (2021) (%)
FIGURE 169 SOUTH AFRICA NUCLEAR MEDICINE PET MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 170 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON RADIATION TYPE, (2021 V/S 2030) (%)
FIGURE 171 SOUTH AFRICA BETA RADIATION THERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 172 SOUTH AFRICA BRACHYTHERAPY MARKET SHARE, BASED ON ISOTOPE, (2021 V/S 2030) (%)
FIGURE 173 SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BASED ON APPLICATION, (2021 V/S 2030) (%)
FIGURE 174 SOUTH AFRICA NUCLEAR MEDICINE SHARE, BASED ON END-USER, (2021 VS 2030) (%)
FIGURE 175 KEY GROWTH STRATEGIES (2020-2021)
FIGURE 176 SWOT: BAYER GROUP
FIGURE 177 SWOT: BRACCO S.P.A
FIGURE 178 SWOT: CARDINAL HEALTH, INC.
FIGURE 179 SWOT: CDH INVESTMENTS
FIGURE 180 SWOT: CURIUM PHARMA
FIGURE 181 SWOT: FUJIFILM HOLDING CORPORATION
FIGURE 182 SWOT: GE HEALTHCARE
FIGURE 183 SWOT: JUBILANT LIFESCIENCES
FIGURE 184 SWOT: LANTHEUS MEDICAL IMAGING INC.
FIGURE 185 SWOT: NOVARTIS INTERNATIONAL AG
FIGURE 186 SWOT: SUMITOMO CHEMICALS
